| Name | Title | Contact Details |
|---|---|---|
Maria Palazon |
Senior Director of Corporate Finance | Profile |
The Faulkner Organization is a family-owned automotive dealership group based in Pennsylvania, founded in 1932. With a legacy of over nine decades, it operates 31 dealerships across Central and Southeastern Pennsylvania, representing 22 vehicle brands. The company specializes in the sale and service of new and pre-owned vehicles. Their offerings include automotive sales, maintenance and repair services, financing and insurance assistance, genuine parts supply, and body shop repair services. The Faulkner Organization is committed to customer satisfaction, employee development, and maintaining high ethical standards in all business dealings.
DUAL North America is a prominent independent underwriting organization based in the United States, part of the global DUAL Group. Established in 2013, it has become a leading program administrator in the insurance sector. The company operates under the Howden-owned DUAL Group, which is recognized as one of the largest managing general agents worldwide, with a presence in 21 countries and over $3.5 billion in gross written premium. The company specializes in expert underwriting solutions across various insurance lines, including commercial property, casualty, financial lines, and surety. DUAL North America offers more than 40 unique products tailored to meet diverse client needs. It also features a robust online platform that enables appointed producers to quote, bind policies, and manage documents digitally. With a network of over 11,000 brokers globally, DUAL North America serves a wide range of clients, from small businesses to large fleets, particularly in regions like California and Texas.
NOBL Wheels, headquartered in the Comox Valley on Vancouver Island, BC, is a leading provider of premium carbon mountain bike rims and wheelsests. Our passion is creating products that use sound building techniques that come alive under aggressive riders and skilled bike handlers.NOBL Wheels 总部位于不列颠哥伦比亚省温哥华岛的 Comox Valley，是优质碳纤维山地自行车轮辋和车轮的领先供应商。我们热衷于创造使用健全构建技术的产品，这些产品在激进的骑手和熟练的自行车处理者下栩栩如生。
The Badminton World Federation (BWF) is the international governing body of the sport of badminton, recognised by the International Olympic Committee (IOC) and the International Paralympic Committee (IPC). It was originally the International Badminton Federation (IBF) which was founded on 5 July, 1934, before being rechristened the Badminton World Federation in 2006. The purpose and objectives of BWF include regulating, promoting, developing and popularising the sport of badminton throughout the world and organising, conducting and presenting international events at the highest level. The BWFs vision is to make badminton a leading global sport accessible to all – giving every child a chance to play for life. Its mission is to lead and inspire all stakeholders; to deliver entertainment through exciting events to drive fan experience; and to create innovative, impactful and sustainable development initiatives. BWF has its headquarters in Kuala Lumpur, Malaysia, with 194 Member Associations worldwide. Poul-Erik Høyer is the BWF President and Thomas Lund is the BWF Secretary General.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.